Clinical trials
Gene Therapy clinical trials
Below are recruiting gene therapy clinical trials, each written for real people, not researchers. We’re tracking 210 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Birmingham, AlabamaAges 18 years+ - NCT06548919Recruiting
Treatment patterns for ESR1-mutated advanced breast cancer
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Suzhou, JiangsuAges 18 years+ - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT04151342Recruiting
Study of Canadian adults with cancer rare DNA changes
This real-world study follows adults in Canada who have cancer that was tested and found to have rare molecular (DNA/protein) changes. It helps researchers understand how these rare findings show up and how care happens in everyday practice.
Calgary, AlbertaAges 18 years+ - NCT05694715RecruitingPhase 1
Test combo treatment for cancers with DNA repair gene mutations
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
San Francisco, CaliforniaAges 18 years+ - NCT07101497RecruitingPhase 2
BN104 as maintenance therapy after stem cell transplant for leukemia
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Suzhou, JiangsuAges 12 years+ - NCT05761899RecruitingPhase 1/Phase 2
Gene-corrected lung immune cells for a rare lung disease
This early-phase study tests a treatment that uses gene-corrected immune cells to treat hPAP, a rare lung condition. The goal is to check safety and see whether the treatment improves breathing and lung function.
Cincinnati, OhioAges 18 years+ - NCT06817694Recruiting
CBT for fear of cancer returning in BRCA1/2 women
This trial tests if cognitive behavioral therapy can reduce fear of cancer recurrence in women with BRCA1/2 mutations who have finished treatment for breast or ovarian cancer. It aims to help you cope with worries about cancer coming back.
Québec, QuebecAges 18 years+ - NCT07622667Recruiting
Gene Study of Cancer Tissue to Predict Treatment Outcomes
This study analyzes genetic information from cancer tumor samples to understand how genes affect treatment response and survival. By looking at leftover tissue or blood samples, researchers hope to better predict which treatments might work best for individual patients.
Guangzhou, GuangdongAges 18 years+ - NCT05769517Recruiting
Using ultrasound to predict BRCA genes from healthy ovaries
This study looks at whether pictures from a vaginal (transvaginal) ultrasound of a healthy ovary can help predict whether someone carries BRCA1 or BRCA2 gene changes. It may help identify people who could benefit from more genetic testing, without needing new ultrasound images.
RomeAges Any age - NCT05805202Recruiting
Study rare gene changes in atypical HUS for tailored care
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
Ranica, BGAges Any age - NCT05134779Recruiting
Study aims to tailor cancer treatment to your biology
This study looks at how genes, the cancer environment, and your immune system interact to develop treatments that work better for people with breast cancer. It may help researchers learn why some treatments work for certain people and not others.
New York, New YorkAges 18–90 - NCT03222674RecruitingPhase 1/Phase 2
CAR T treatment for acute myeloid leukemia in children and adults
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
Shenzhen, GuangdongAges 2–75 - NCT06481735RecruitingPhase 1/Phase 2
Modified donor CAR-T for B-cell leukemia
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Beijing, Beijing MunicipalityAges 16–70 - NCT06014073RecruitingPhase 1/Phase 2
A new CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a special type of CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to standard treatments. The CAR-T cells are made from a donor and have genes removed to work better. The goal is to see if this treatment is safe and effective.
BeijingAges 18–70 - NCT04160455Recruiting
Study of GALIG proteins in adults with HIV on or off treatment
This study looks at how “GALIG” gene products affect the body’s internal recycling process (called autophagy) in people living with HIV. It may help researchers understand differences between people on HIV treatment, starting treatment, or not currently taking it.
OrléansAges 18 years+ - NCT06798298Recruiting
Long-term safety study of gene modified T cell treatment
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
Nashville, TennesseeAges 18 years+ - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06928701Recruiting
Diet and exercise for early breast cancer before surgery
This trial tests whether a personalized nutrition and exercise program can improve treatment response by changing how your body and immune system react to breast cancer before surgery. It is for women newly diagnosed with early-stage breast cancer who will receive neoadjuvant therapy (treatment before surgery).
Novara, NovaraAges 18 years+ - NCT04427449RecruitingPhase 1/Phase 2
4SCAR-CD44v6 t cell therapy for cancer patients
This trial tests a new treatment using your own immune cells, called T cells, which are modified in a lab to find and attack cancer cells that have a specific marker called CD44v6. It is for patients whose tumors show this marker and who are generally well enough to undergo cell therapy.
Shenzhen, GuangdongAges 6 months–75 years - NCT07215416RecruitingPhase 1/Phase 2
Gene therapy for ataxia-telangiectasia with specific ATM mutation
This trial tests a new genetic medicine designed for people with A-T who have a specific ATM gene change. It aims to see if the treatment is safe and if it can improve symptoms.
Boston, MassachusettsAges birth–17 years - NCT03192501Recruiting
Using prior scans to guide cancer treatment choices
This trial tests whether using existing “PACS” scan images to guide individualized cancer treatment (compared with standard care) can improve outcomes for people with advanced or metastatic cancer. It may help doctors make more precise treatment decisions using your past imaging.
Guangzhou, GuangdongAges 18–70
Hear when a new Gene Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gene therapy?
- Yes. Clin2 currently lists 210 recruiting gene therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gene therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gene therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.